The Cognizant Life Sciences business, a trusted partner to some of the world's top pharma and biotech companies, and Florence, the electronic investigator site file (eISF) and remote connectivity platform used in 8,500 study sites across 34 countries, announced their joint initiative to enhance collaboration between clinical trial sites and sponsors. The strategic relationship leverages the two companies’ platforms to allow for seamless end-to-end exchange of documents from sponsor electronic trial master file (eTMF) systems to the Florence eRegulatory binder, through Cognizant Shared Investigator Platform (SIP). This joint offering accelerates site activation, reduces site burden, simplifies workflows and streamlines stakeholder communication.
Cognizant SIP is the only open, collaborative clinical trial technology platform, leveraging one environment across multiple sponsors and operating via common workflows and documents. Florence eBinders™ eISF helps sites save time by reducing paperwork and giving clinical trial sponsors instant remote access to a vast majority of their study sites.
The strategic collaboration establishes a way for sponsors to migrate from paper-based binder processes to modern, digital document exchange with automated workflows and e-signature capabilities, enabling sites and sponsors to work together more seamlessly on both regulatory and source content.
“Sites are required to perform manual workflows whenever they exchange documents with sponsors throughout the lifecycle of a study, relying on paper, email and antiquated online document repositories,” said Srinivas Shankar, Global Head of Life Sciences, Cognizant. “By partnering with Florence, the leader in digital site workflows, we solidify our site-centric focus to enhance the overall clinical trial experience while accelerating study timelines.”
Cognizant SIP is utilized by more than 155,000 users and over 26,000 sites across 98 countries. As such, Cognizant SIP enables sponsors and contract research organizations to connect with sites across the globe and facilitate study participation by multicultural, diverse patient populations, improving therapeutics’ safety and efficacy.
More than 8,500 research teams in 34 countries manage their eISF on Florence. The platform increases compliance and reduces document cycle times by 40% during a clinical study with eSignatures, eLogs, source capture and management solutions, fillable forms, document status alerts and remote site access for monitoring and source review.
“This relationship connects SIP sponsors directly to the Florence network of digital research-ready sites,” said Ryan Jones, CEO, Florence. “In addition, sites not yet harnessing the Florence ecosystem who participate in a SIP study get a jump start on their digital transformation, ultimately helping speed study timelines and getting them into more desirable trials in the future.”
To learn more about how this new offering will power clinical operations, visit the Cognizant SIP website.